Pricing Log in Create free account

Aktis Oncology, Inc. (AKTS) vs Monte Rosa Therapeutics, Inc. (GLUE)

Aktis Oncology, Inc. and Monte Rosa Therapeutics, Inc. are both Biotechnology companies. Aktis Oncology, Inc. and Monte Rosa Therapeutics, Inc. are of similar size ($890.5M and $863.4M). Monte Rosa Therapeutics, Inc. has the higher net margin (−560.9% vs −782.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Monte Rosa Therapeutics, Inc. leads on 8 and Aktis Oncology, Inc. on 5.

Valuation

Metric AKTS GLUE Biotechnology median
P/E n/m n/m 8.50
P/S 86.22 34.41 9.71
P/B 1.72 2.03 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 32.66 12.79 9.21
Earnings yield (277.60%) (18.07%) (33.15%)
Free cash flow yield (16.73%) (3.25%) (25.50%)

Profitability

Metric AKTS GLUE Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (939.13%) (633.04%) 0.00%
Net margin (781.95%) (560.85%) 0.00%
Free cash flow margin (1,442.91%) (111.66%) 0.00%
Return on equity (34.45%) (42.66%) (56.36%)
Return on assets (22.22%) (30.67%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AKTS GLUE Biotechnology median
Revenue growth (TTM) — (83.86%) 6.02%
EPS growth (last fiscal year) (25.43%) 53.06% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AKTS GLUE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.33 10.58 4.72
Net debt to EBITDA 2.95 8.22 0.96

Dividend

Metric AKTS GLUE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AKTS GLUE Biotechnology median
Market cap 890.47m 863.37m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack